Moxetumomab pasudotox-tdfk

(Lumoxiti®)

Lumoxiti®

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 1 mg)
Drug ClassCD22-directed cytotoxins
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Product Monograph / Prescribing Information

Document TitleYearSource
Lumoxiti (moxetumomab pasudotox-tdfk) Prescribing Information.2022AstraZeneca Pharmaceuticals LP, Wilmington, DE

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. 2021Clinical Lymphoma, Myeloma & Leukemia
Treatment of hairy cell leukemia. 2020Expert Review of Hematology